Researchers Studying Maximum Tolerated Dose of IV Infusion and Radiation Therapy in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (KONQUER)

Phase: Recruiting

First Posted: January

Condition(s): Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma (DMG)

NCT Number: NCT04771897 Other Study ID Number(s): BXQ-350AD

What Is the Purpose of This Study?

To test the safety and determine the maximum tolerated dose of an IV infusion drug in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or diffuse midline glioma (DMG).

Who Can Take Part in This Study?

People who may be eligible for this study:

  • Have radiographically suspected or histologically confirmed newly diagnosed DIPG or DMG.
  • Are 1 to 30 years old.

For a full list of eligibility requirements, visit https://www.clinicaltrials.gov/study/NCT04771897

What Will Happen During This Study?

All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy. The study is divided into two parts.

  • Part 1 will enroll patients at increasing dose levels of BXQ-350 to determine the maximum tolerated dose over 12 months.
  • Part 2 will enroll patients requiring a biopsy to assess BXQ-350 concentrations in the biopsied tumor over 12 months.

Principal Investigator

Maryam Fouladi
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to neuro-oncology